Diabetes
News
Hypoglycemia in diabetes occurs across glycemic control levels
Major finding: The relative risk of hypoglycemia was greatest in those with "near normal" and "very poor" HbA1c levels (RR, 1.25 and 1.16,...
News
Controversial diabetes drug not associated with increased CV risk in patients with CAD
Major finding: No increased risk of major cardiovascular events associated with rosiglitazone was identified in a study of patients with type 2...
News
Glucose, insulin measures unrelated to AD pathology
Major finding: There were no significant differences in mean nondementia/dementia values for fasting glucose (100/98 mg/dL), fasting insulin (9.6/...
News
When to think Cushing’s syndrome in type 2 diabetes
Conference Coverage
Discontinuation rates high with type 2 diabetes drugs
Major finding: Twelve months after a very large group of type 2 diabetes patients were placed on a GLP-1 agonist, 89% had discontinued the drug, a...
Conference Coverage
Statins for low CVD risk? Check glucose first
Major finding: In patients with a 5-year CVD risk of 5% and normal glucose tolerance, statins were not cost effective ($101,800 per quality-...
Conference Coverage
Weight-loss program for veterans cut diabetes risk
Major finding: Twenty-eight percent of heavy patients who were active participants in a novel lifestyle change program experienced a clinically...
Conference Coverage
Overtreatment common in high-risk diabetes patients
Major finding: Nearly half of diabetes patients at high risk for serious hypoglycemia, based upon advanced age, renal dysfunction, or cognitive...
Conference Coverage
Osteoprotegerin ups risk of vascular events in type 1 diabetes
Major finding: Elevated osteoprotegerin levels were a significant independent risk marker for incident cardiovascular events (hazard ratio, 1.21)...
Conference Coverage
Novel insulin/GLP-1 combo succeeds in phase III trial
Major finding: Patients with type 2 diabetes not adequately controlled on oral therapy experienced a mean 1.91% reduction in HbA1c to a final...
News
Add-on dapagliflozin achieves combined weight/HbA1c reduction more often than glipizide
Major Finding: At week 52, 67% of type 2 diabetes patients on dapagliflozin had reductions in both HbA1c and weight, compared with 21% on...